Prostatype Genomics AB (PROGEN) AI Stock Analysis

• Market Cap: kr14.21M
• Dividend Yield: N/A
• Average Volume (3M): 300.11K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.58
• Revenue Growth: -67.76%
• EPS Growth: 95.76%
• Country: SE
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 37,000,263
• 10 Day Avg. Volume: 460,844
• 30 Day Avg. Volume: 300,114
• PEG Ratio: -0.06
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 167.53
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -2.7
• Revenue Forecast (FY): kr5.07M

• Rating: 43 Neutral
• Price Target: kr0.43 ▼(-42.40% Downside)

The score is primarily held down by weak financial performance (ongoing losses and negative free cash flow with reliance on financing). Technicals add additional pressure due to a broader downtrend versus longer-term moving averages and a negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Proprietary Genomic Test

Owning a proprietary genomic test provides a durable product moat: differentiated clinical data and IP can drive clinician adoption, recurring test volumes, and partnership interest with pharma and research institutions, supporting long-term revenue streams if commercialized.

Conservative Balance Sheet (Low Leverage)

A strong equity ratio and no reported debt give the company financial flexibility to fund R&D or commercial launches via equity without near-term leverage risk. This reduces solvency pressure and supports longer-term strategic choices for growth investments or partnerships.

Secular Tailwinds: Personalized Medicine

Structural growth in precision medicine expands the addressable market for prostate genomic tests. Persistent adoption trends among clinicians and pharma interest in biomarkers create durable demand potential, improving long-term revenue visibility if the company scales commercial execution.

Negative Factors

Persistent Losses and Cash Burn

Ongoing operational losses and sustained negative free cash flow indicate the business currently consumes capital rather than generating it. Over months, this necessitates external financing, constrains reinvestment in sales or R&D, and raises execution risk toward achieving profitability.

Sharp Revenue Contraction

A material decline in revenue signals weak commercial traction or loss of demand. Such a drop impairs operating leverage, undermines gross margin sustainability, and lengthens the timeline to positive cash generation, challenging the firm's ability to scale its test business sustainably.

Very Limited Operational Scale

A tiny headcount constrains lab throughput, sales coverage, regulatory capacity, and product development. Scaling to serve hospitals, labs, and pharma partners will require sustained hiring and investment, increasing burn and execution complexity over the coming months.

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision medicine by providing innovative genomic solutions that help clinicians make informed decisions regarding patient management and personalized treatment plans. PROGEN's core product is its proprietary genomic test, which analyzes tumor characteristics to predict disease progression and guide therapeutic choices for prostate cancer patients.

How the Company Makes Money

Prostatype Genomics AB generates revenue primarily through the sale of its genomic testing services to healthcare providers and institutions. The company may charge fees for each test conducted, which can vary based on the complexity and comprehensiveness of the analysis. Additionally, PROGEN could engage in partnerships with pharmaceutical companies and research institutions for collaborative studies or clinical trials, providing further revenue opportunities through grants, licensing agreements, or shared profits from joint ventures. The growing demand for personalized medicine and advancements in genomic technologies also position PROGEN to capitalize on expanding markets and increased adoption of its services.

Prostatype Genomics AB Financial Statement Overview

Summary

Prostatype Genomics AB faces significant financial challenges with ongoing losses, inconsistent revenue growth, and reliance on external financing. While the balance sheet shows a strong equity position, the lack of profitability and negative cash flows indicate operational inefficiencies and potential sustainability risks.

Income Statement

Prostatype Genomics AB has consistently experienced negative net income and negative EBIT over the years, indicating ongoing operational losses. The gross profit margins are not sustainable as they are driven by minimal revenue and high costs. The revenue growth is highly inconsistent, with recent declines suggesting challenges in expanding its market presence.

Balance Sheet

The company maintains a healthy equity ratio, suggesting a strong equity position relative to total assets. However, the absence of total debt in recent reports reflects a lack of leverage, which could indicate limited access to external financing or a conservative financial strategy. The return on equity is negative due to ongoing losses, highlighting inefficiencies in generating returns from shareholders' equity.

Cash Flow

Prostatype Genomics AB's cash flow situation is concerning, with consistent negative free cash flow, indicating that the company is not generating enough cash from operations to fund its capital expenditures. The high operating cash outflow compared to net income suggests operational inefficiencies. The company relies heavily on financing cash flow to meet its cash needs, which could pose sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.00K	199.00K	1.36M	683.00K	10.00K	683.88K
Gross Profit	-11.24M	1.92M	3.73M	683.00K	2.51M	-14.20M
EBITDA	-41.42M	-37.40M	-38.02M	-26.79M	-15.46M	-15.76M
Net Income	-45.31M	-41.05M	-41.44M	-29.09M	-15.63M	-17.41M
Balance Sheet
Total Assets	43.84M	41.97M	49.22M	30.95M	40.20M	33.66M
Cash, Cash Equivalents and Short-Term Investments	12.93M	9.42M	2.68M	11.49M	20.33M	15.86M
Total Debt	0.00	67.00K	11.67M	867.00K	1.27M	1.47M
Total Liabilities	7.36M	8.50M	24.55M	4.80M	4.30M	5.37M
Stockholders Equity	36.48M	33.47M	24.67M	26.15M	35.91M	28.29M
Cash Flow
Free Cash Flow	-39.09M	-52.57M	-37.70M	-27.69M	-18.58M	-14.74M
Operating Cash Flow	-38.58M	-44.71M	-29.14M	-27.69M	-16.08M	-14.71M
Investing Cash Flow	-3.15M	-8.36M	-8.57M	0.00	-2.50M	-3.26M
Financing Cash Flow	52.87M	59.75M	28.91M	18.85M	23.05M	31.14M

Prostatype Genomics AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Neutral. The current price of 0.75 is above the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.54, and below the 200-day MA of 0.95, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.01 is Neutral, neither overbought nor oversold. The STOCH value of 65.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PROGEN	43 Neutral	kr14.21M	-0.19	-181.36%	―	-67.76%	95.76%
LARK	43 Neutral	kr46.14M	-0.99	―	8.47%	-94.12%	-25.83%
STABL	42 Neutral	kr16.67M	-1.45	-91.33%	―	―	64.02%
LIDDS	42 Neutral	kr6.82M	-1.03	-132.58%	―	―	86.26%
BIOVIC.B	41 Neutral	kr127.25M	-0.79	-72.82%	―	40.91%	57.92%